Topic: pneumococcal disease
Behind the under-pressure blockbuster Prevnar 13 are several pipeline vaccines Pfizer hopes will propel future growth.
Pfizer's Prevnar turned in consensus-beating sales of $1.53 billion in Q4, thanks to government purchases internationally and in the U.S.
Astellas just forged a licensing deal with Affinivax to develop a pneumococcal vaccine. Their target? Pfizer’s Prevnar 13—the world’s best-selling vaccine.
International charity Médecins Sans Frontières has urged Pfizer for years to cut the prices on its pneumococcal vaccines. After all, Prevnar and Prevnar 13 deliver billions in sales, and vaccinating children in developing countries is very costly. So why did the charity turn down Pfizer's offer of a million free doses?